A phase i study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

British Journal of Cancer

Volumn 104, Issue 5, 2011, Pages 750-755

  Khan, O A ^a   Gore, M ^b   Lorigan, P ^c   Stone, J ^d   Greystoke, A ^e   Burke, W ^f   Carmichael, J ^f   Watson, A J ^e   McGown, G ^e   Thorncroft, M ^e   Margison, G P ^e   Califano, R ^c   Larkin, J ^b   Wellman, S ^a   Middleton, M R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d KuDOS Pharmaceuticals   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f ASTRAZENECA   (United Kingdom)

Author keywords

chemotherapy; dacarbazine; melanoma; PARP; resistance

Indexed keywords

DACARBAZINE; OLAPARIB;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LETHARGY; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; THROMBOCYTOPENIA;

EID: 79952281417     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.8     Document Type: Article

References (17)

1. Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, Giannotti B, Queirolo P, Tribbia G, Bernengo MG (1994) Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12: 806-811 (Pubitemid 24110922)
2. Chalmers AJ (2009) The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 89: 23-40
3. Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, Oliver J, Rolli V, Menissier-de Murcia J, de Murcia G (1999) Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81: 69-75
4. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748-759 (Pubitemid 37527210)
5. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134
6. Fromme JC, Banerjee A, Verdine GL (2004) DNA glycosylase recognition and catalysis. Curr Opin Struct Biol 14: 43-49 (Pubitemid 38249591)
7. Harrison KL, Wood M, Lees NP, Hall CN, Margison GP, Povey AC (2001) Development and application of a sensitive and rapid immunoassay for the quantitation of N7-methyldeoxyguanosine in DNA samples. Chem Res Toxicol 14: 295-301 (Pubitemid 32238489)
8. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh Jr VM, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51: 6581-6591
9. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158-166 (Pubitemid 30036349)
10. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14: 7917-7923
11. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, Snow K, Dewji K, Calvert H (2006) First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol (Meeting Abstracts) 24: 8013
12. Quirt I, Verma S, Petrella T, Bak K, Charette M (2007) Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 12: 1114-1123 (Pubitemid 350007023)
13. Tentori L, Portarena I, Vernole P, De Fabritiis P, Madaio R, Balduzzi A, Roy R, Bonmassar E, Graziani G (2001) Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) poly-merase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother Pharmacol 47: 361-369 (Pubitemid 32640776)
14. Tentori L, Turriziani M, Franco D, Serafino A, Levati L, Roy R, Bonmassar E, Graziani G (1999) Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 13: 901-909 (Pubitemid 29292141)
15. Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37: 1-3 (Pubitemid 32613627)
16. Virag L, Szabo C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375-429
17. Watson AJ, Middleton MR, McGown G, Thorncroft M, Ranson M, Hersey P, McArthur G, Davis ID, Thomson D, Beith J, Haydon A, Kefford R, Lorigan P, Mortimer P, Sabharwal A, Hayward O, Margison GP (2009) O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer 100: 1250-1256